Merck & Co Inc

NYSE:MRK   12:02:30 PM EDT
78.52
-0.17 (-0.22%)
Regulatory, Earnings Announcements

Merck Announces Positive Topline Results From Two Phase 3 Adult Studies Evaluating V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial

Published: 09/09/2020 12:28 GMT
Merck & Co Inc (MRK) - Merck Announces Positive Topline Results From Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial.
Merck & Co Inc - Application for V114 Licensure in Adults to Be Submitted by Year-end.
Merck & Co Inc - in Both Studies, V114 Was Generally Well Tolerated.
Merck & Co Inc - Two Phase 3 Studies Evaluating V114 Met Their Primary Immunogenicity Objectives.
Merck & Co Inc - Pneu-age Study Also Met Key Secondary Immunogenicity Objective.
Merck & Co - in Both Studies, V114 Had a Safety Profile Comparable to Pcv13 and Consistent With That Observed for V114 in Previously Reported Studies.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.